ReviewThrombosis research2018
An update on factor XI structure and function.
Review in Thrombosis research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 1 synthesis or guideline pooled it, 163 citations in OpenAlex.
- The clinical management of factor XI deficiency in pregnant women.Expert review of hematology · 2020Pooled it
- FXI and FXII in experimental stroke and FXI in clinical stroke trials.Neurological research and practice · 2026Review
- Structural insights into the exosite-mediated activation of factor IX by factor XIa using cryogenic electron microscopy.Journal of thrombosis and haemostasis : JTH · 2026Article
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of KN060, a humanized anti-FXI/FXIa dual-domain antibody, following single ascending doses in healthy Chinese subjects.Research and practice in thrombosis and haemostasis · 2026Article
- The Discovery of a Novel Anticoagulant Mechanism: Factor XI Activation Inhibitors.ACS pharmacology & translational science · 2025Article
- Recent advances in vascular thiol isomerases: insights into structures, functions in thrombosis and antithrombotic inhibitor development.Thrombosis journal · 2025Review
- Identification and characterization of factor XI autoantibodies in 2 patients with systemic lupus erythematosus: insights into mechanisms of acquired factor XI deficiency.Research and practice in thrombosis and haemostasis · 2025Article
- Uncovering glycolysis-driven molecular subtypes in diabetic nephropathy: a WGCNA and machine learning approach for diagnostic precision.Biology direct · 2025Article
- Perioperative anesthesia management of high-molecular-weight kininogen deficiency: a case report and literature review.Frontiers in medicine · 2025Article
- Protonated-chitosan sponge with procoagulation activity for hemostasis in coagulopathy.Bioactive materials · 2024Article
- Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings.Haematologica · 2024Review
- Review
- Gene-Gene Interaction Between Factor-Neurology · 2024Article
- The spectrum of factor XI deficiency in Southeast China: four recurrent variants can explain most of the deficiencies.Orphanet journal of rare diseases · 2024Article
- Is anticoagulative therapy in systemic sclerosis to be reconsidered?Journal of scleroderma and related disorders · 2024Article
- Biology of factor XI.Blood · 2024Review
- Discovery of α-Amidobenzylboronates as Highly Potent Covalent Inhibitors of Plasma Kallikrein.ACS medicinal chemistry letters · 2024Article
- Review
- [Molecular mechanism analysis of a family with hereditary coagulation F Ⅺ deficiency caused by compound heterozygous mutations].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition.Current research in pharmacology and drug discovery · 2024Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 3 countries.
Funding
Abstract
Factor XI (FXI) is the zymogen of a plasma protease, factor XIa (FXIa), that contributes to thrombin generation during blood coagulation by proteolytic activation of several coagulation factors, most notably factor IX (FIX). FXI is a homolog of prekallikrein (PK), a component of the plasma kallikrein-kinin system. While sharing structural and functional features with PK, FXI has undergone adaptive changes that allow it to contribute to blood coagulation. Here we review current understanding of the biology and enzymology of FXI, with an emphasis on structural features of the protein as they relate to protease function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.